- Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System
- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates
Key statistics
As of last trade Heron Therapeutics Inc (AXD2:STU) traded at 2.90, -18.43% below its 52-week high of 3.56, set on Jun 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.89 |
---|---|
High | 3.00 |
Low | 2.89 |
Bid | 2.89 |
Offer | 2.97 |
Previous close | 2.90 |
Average volume | 26.67 |
---|---|
Shares outstanding | 150.65m |
Free float | 149.60m |
P/E (TTM) | -- |
Market cap | 482.09m USD |
EPS (TTM) | -0.6156 USD |
Data delayed at least 15 minutes, as of Jul 23 2024.
More ▼